Impact of First-Line Therapy on Long-Term Outcomes in nAMD and DME

Opinion
Video

Experts discuss the importance of optimizing first-line therapies in the treatment of retinal diseases like neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME).

Summary

In this series, esteemed panelists David Eichenbaum, MD Diana Do, MD Kenny Fan, MD, MBA, Seenu Hariprasad, MD, and David Brown, MD discusses the impact of novel therapies in retinal disease management. Experts discuss the evolving landscape of retinal disease treatment, focusing on the impact of first-line therapy and its impact on long-term disease progression. Kenny Fan, MD, MBA emphasizes the significance of optimizing first-line therapy to achieve the best outcomes for patients. The discussion emphasizes the critical role of timely fluid removal, while reducing fluid fluctuations, in enhancing patient overall quality of life.

This summary was AI-generated and edited for clarity.

Related Videos
Peter A. Campochiaro, MD: RGX-314 for nAMD | Image Credit: Johns Hopkins Medicine
Deepak Sambhara, MD | Image Credit: American Society of Retina Specialists
© 2024 MJH Life Sciences

All rights reserved.